Abstract
Degenerative aortic stenosis is the most frequently acquired heart valve disease and the most com¬mon indication for valve surgery. However, at least 30% of patients with aortic stenosis do not undergo surgical aortic valve replacement (SAVR), owing to advanced age or its associated comorbidities. For these patients, transcatheter aortic valve replacement (TAVR) may be a worthwhile alternative. PARTNER Cohort B trial demonstrated the efficacy of TAVR compared with conventional treatment for inoperable patients, and Cohort A trial disclosed noninferiority of TAVR compared with SAVR in high risk patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
